Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viread approval recommended

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

At Oct. 3 meeting, FDA's Antiviral Drugs Advisory Committee unanimously recommends use of Gilead's antiviral Viread (tenofovir disoproxil fumarate) in adult patients with HIV infection who have received prior antiretroviral therapy. Due to a lack of data in treatment-naive patients and other concerns, a majority of committee members favored restricting use to treatment-experienced patients. Gilead is conducting a 601-patient Phase III trial in treatment-naive subjects, and analysis of results should be completed in the first half of 2002
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel